AKCI is an AURKC–IκBα interaction inhibitor (IC50 = 24.9 μM) that induces G2/M cell cycle arrest by modulating the p53/p21/CDC2/cyclin B1 pathway, inhibits cell migration and invasion, reduces colony formation and tumor growth in MDA-MB-231 cells, and is used in breast cancer research.